List of Excipients in Branded Drug HYDROCORTISONE VALERATE

Generic Drugs Containing HYDROCORTISONE VALERATE

Company	Ingredient	NDC	Excipient
Cosette Pharmaceuticals Inc	hydrocortisone valerate	0713-0560	CARBOMER HOMOPOLYMER TYPE B
Cosette Pharmaceuticals Inc	hydrocortisone valerate	0713-0560	LIGHT MINERAL OIL
Cosette Pharmaceuticals Inc	hydrocortisone valerate	0713-0560	METHYLPARABEN
Cosette Pharmaceuticals Inc	hydrocortisone valerate	0713-0560	PETROLATUM
Cosette Pharmaceuticals Inc	hydrocortisone valerate	0713-0560	PROPYLENE GLYCOL
Cosette Pharmaceuticals Inc	hydrocortisone valerate	0713-0560	SODIUM LAURYL SULFATE
Cosette Pharmaceuticals Inc	hydrocortisone valerate	0713-0560	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS

What are the Most Frequently-Used Excipients in HYDROCORTISONE VALERATE?

# Of NDCs	Excipient
2	ACRYLAMIDE
2	CARBOMER HOMOPOLYMER TYPE B
9	CARBOMER HOMOPOLYMER TYPE C
1	CITRIC ACID MONOHYDRATE
2	ISOHEXADECANE
1	LIGHT MINERAL OIL
10	METHYLPARABEN

Hydrocortisone Valerate Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

Hydrocortisone valerate is a mature topical corticosteroid with commercial opportunity concentrated in formulation performance, tolerability, dosage-form convenience, supply reliability, and regulated generic substitution. The strongest strategy is to preserve the reference product’s therapeutic and microstructural profile for an ANDA while developing differentiated creams, ointments, lotions, gels, foams, or emulsion systems through a 505(b)(2) pathway where the commercial benefit justifies added regulatory cost.

What is the commercial profile of hydrocortisone valerate?

Hydrocortisone valerate is a synthetic corticosteroid ester used topically to treat corticosteroid-responsive dermatoses, including atopic dermatitis, contact dermatitis, seborrheic dermatitis, and psoriasis in appropriate patients. U.S. products have generally been marketed at 0.2% strength in cream, ointment, and lotion dosage forms.

Hydrocortisone valerate is commonly classified as a medium-potency topical corticosteroid in U.S. labeling. Potency depends on formulation, concentration, vehicle, application site, and test method. A formulation change can alter skin delivery even when the active ingredient concentration remains 0.2%.[1]

Commercial attribute	Hydrocortisone valerate
Active ingredient	Hydrocortisone valerate
Common topical strength	0.2%
Main dosage forms	Cream, ointment, lotion
Therapeutic category	Topical corticosteroid
Primary customers	Dermatologists, pediatricians, primary-care physicians, consumers with prescriptions
Reference brand historically associated with product	Westcort
Regulatory routes	ANDA, 505(b)(2), or new NDA depending on formulation and claims
Main competitive products	Hydrocortisone butyrate, desonide, triamcinolone acetonide, fluocinolone acetonide, betamethasone valerate
Main commercial constraints	Generic price erosion, corticosteroid safety concerns, mature market, limited exclusivity

The product is unlikely to support a premium solely because of the active ingredient. Commercial value must come from delivery, tolerability, ease of application, packaging, access, or a clinically meaningful use case.

What excipients are used in hydrocortisone valerate products?

Hydrocortisone valerate products use excipient systems selected to solubilize or disperse a lipophilic corticosteroid, control release from the vehicle, stabilize the emulsion, preserve the product, and improve skin feel.

Typical excipient categories include:

Excipient function	Common candidates
Oil phase and occlusion	White petrolatum, mineral oil, paraffin, fatty alcohols
Emulsification	Glyceryl monostearate, polysorbates, sorbitan esters, polyoxyl stearates
Humectancy and solvent function	Propylene glycol, glycerin
Thickening and rheology	Carbomers, cetostearyl alcohol, cetyl alcohol, stearyl alcohol, cellulose derivatives
pH adjustment	Sodium hydroxide, citric acid, phosphate buffers
Preservation	Parabens, phenoxyethanol, benzyl alcohol, sorbic acid systems
Chelation and stability	Disodium edetate
Sensory modification	Silicones, volatile emollients, selected esters
Packaging compatibility	Aluminum tubes, laminate tubes, plastic tubes, pump systems

The exact excipient composition differs by manufacturer and dosage form. FDA labeling and DailyMed product records should control the final inactive-ingredient assessment for each marketed product.[2]

How should the excipient system be designed?

The formulation objective is not maximum solubility. It is controlled delivery into the stratum corneum while limiting systemic absorption and avoiding excessive accumulation in the vehicle.

Hydrocortisone valerate is lipophilic. A dispersed suspension, partially solubilized system, or multiphase emulsion can produce different release and skin-penetration profiles. The critical variables include:

1. Drug particle size and crystal form.
2. Degree of drug solubilization.
3. Oil-to-water ratio.
4. Emulsion droplet size.
5. Vehicle viscosity and yield stress.
6. Surfactant concentration.
7. pH and buffer capacity.
8. Preservative distribution between phases.
9. Water activity.
10. Packaging and shear history.

A generic cream that matches only the qualitative and quantitative excipient list may still differ in microstructure and performance. FDA’s topical-product framework places increasing weight on comparative physicochemical and structural characterization, often referred to as Q3 characterization, together with in vitro release testing and other bioequivalence evidence.[3]

What excipient strategy is appropriate for an ANDA?

The lowest-risk strategy is a reference-aligned cream, ointment, or lotion using the same inactive ingredients where feasible and the same qualitative and quantitative excipient composition where practical.

Reference-aligned cream

A cream is the broadest commercial opportunity because it balances spreadability, patient acceptability, and non-occlusive use. A conventional cream may use:

• Purified water as the continuous phase.
• Propylene glycol or glycerin as humectant and cosolvent.
• Glyceryl monostearate and fatty alcohols as structural emulsifiers.
• Mineral oil or petrolatum as emollient and occlusive components.
• A nonionic surfactant system.
• A preservative system appropriate for the final water activity and packaging.

For an ANDA, the development team should prioritize:

• Matching active concentration.
• Matching dosage form.
• Matching excipient identity and concentration where required.
• Matching pH and viscosity range.
• Matching globule-size distribution and microscopic structure.
• Demonstrating comparable IVRT profiles.
• Controlling polymorphism and drug crystallization during shelf life.

Ointment

An ointment has the highest occlusivity and may be valuable for dry, lichenified, or highly desiccated lesions. Petrolatum-based systems usually provide strong barrier effects and good chemical stability because they contain little or no water.

The disadvantages are greasiness, transfer to clothing, poor cosmetic acceptance, and reduced suitability for hairy or intertriginous sites. An ointment strategy is commercially strongest when positioned around barrier support, nighttime use, and severe dryness rather than broad cosmetic appeal.

Lotion

A lotion can improve spreadability over large or hairy areas. It is typically less occlusive and may dry more quickly than a cream or ointment. The principal formulation risks are sedimentation, phase separation, preservative failure, and dose nonuniformity.

A lotion may create an opportunity in seborrheic dermatitis, scalp-adjacent applications, and larger body surface areas. The product should avoid excessive alcohol if the intended population includes patients with barrier-disrupted or eczematous skin.

What differentiated excipient opportunities exist?

The best opportunities are those that solve a specific adherence or tolerability problem without creating a new regulatory burden disproportionate to market size.

Preservative-minimized or preservative-free cream

A preservative-free or preservative-minimized product could appeal to patients with sensitive skin, recurrent dermatitis, or known preservative intolerance. The commercial case depends on packaging.

A multidose airless pump, unit-dose package, or sealed metered dispenser could reduce contamination risk. The key development issues are:

• Microbiological protection during use.
• Container-closure integrity.
• Pump dose uniformity.
• Compatibility between the vehicle and packaging.
• Stability after repeated actuation.
• Cost per treatment course.

A preservative-free claim is not equivalent to a lower-irritancy claim. The full formulation and package must support the intended positioning.

Fragrance-free, low-irritancy cream

Fragrance-free products are commercially relevant in atopic dermatitis and pediatric dermatology. The excipient strategy should minimize unnecessary sensitizers and irritants while preserving emulsion stability.

Potentially useful design choices include:

• Nonionic surfactants.
• Lower levels of propylene glycol where irritation is a concern.
• No fragrance or essential oils.
• Reduced alcohol content.
• Controlled pH near the skin’s mildly acidic range.
• Limited use of high-sensitization preservatives.

A lower-irritancy profile requires comparative tolerability evidence. It should not be inferred solely from an ingredient list.

Barrier-supportive emulsion

A cream incorporating physiologic lipids, ceramide-related materials, cholesterol, or fatty acids could support a premium product concept. The principal limitation is regulatory classification. If the product makes only cosmetic or barrier-support claims, it may fall outside the intended drug labeling. If the formulation or labeling implies treatment of a corticosteroid-responsive disease, the product remains subject to drug requirements.

A barrier-supportive vehicle may improve patient acceptability, but it can also alter hydrocortisone valerate release and penetration. Drug-excipient compatibility and IVRT must be assessed early.

Silicone-enhanced cream

Silicones can improve spreadability, reduce tack, and produce a drier after-feel. They may be useful in daytime products or formulations intended for visible areas.

The risk is that volatile or nonvolatile silicone changes the partitioning of hydrocortisone valerate and affects release. The formulation should be evaluated for drug distribution, evaporation behavior, film formation, and delivery after application.

Foam or aerosolized vehicle

Foams can improve application to hair-bearing areas and reduce the need for rubbing. They may provide commercial differentiation over conventional cream and ointment products.

The challenges are substantial:

• New container and actuator system.
• Propellant compatibility.
• Flammability controls where applicable.
• Dose delivery and plume characterization.
• Microstructural stability.
• Higher manufacturing and packaging costs.
• Potential 505(b)(2) or new-drug regulatory requirements.

A foam can support a premium price, but it requires a larger development program than a standard generic cream.

What regulatory pathway applies to new hydrocortisone valerate formulations?

ANDA pathway

An ANDA is the preferred route for a formulation that matches an approved reference product in active ingredient, strength, dosage form, route, and relevant pharmaceutical characteristics. The applicant must establish bioequivalence under the applicable FDA requirements.

For topical dermatological products, evidence may include:

• Comparative qualitative and quantitative composition.
• Product characterization.
• In vitro release testing.
• In vitro permeation testing where relevant.
• Comparative physical and structural characterization.
• Clinical endpoint studies or pharmacodynamic studies when required.
• Microbiological quality and preservative-effectiveness testing.
• Stability and package-compatibility data.

The precise evidence package depends on FDA product-specific guidance and the reference product selected.[3,4]

505(b)(2) pathway

A 505(b)(2) application may be appropriate for a materially different dosage form, vehicle, strength, delivery system, or labeling concept that relies in part on FDA’s prior findings for hydrocortisone valerate products.

Examples could include:

• A foam for scalp or hair-bearing areas.
• A spray or metered-dose delivery system.
• A novel emulsion with a distinct clinical-use profile.
• A product designed for a new application site.
• A formulation with a different concentration or dosing regimen.

The 505(b)(2) route can support differentiation but may create patent-certification, exclusivity, clinical, and labeling issues. It is generally less attractive for a minor excipient substitution that cannot command a durable price premium.

What patent and exclusivity issues affect hydrocortisone valerate?

Hydrocortisone valerate is an old active ingredient, and commercial exclusivity is expected to be limited compared with recently approved dermatology products. The core molecule and conventional dosage forms are unlikely to provide meaningful new-chemical-entity exclusivity.

Orange Book status

The relevant Orange Book analysis should distinguish:

• Listed patents for a specific reference product.
• Drug-substance patents.
• Drug-product or formulation patents.
• Method-of-use patents.
• Regulatory exclusivity codes.
• Patent expiry dates.
• Any pediatric exclusivity extension.
• Paragraph IV certifications by ANDA applicants.

FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations is the controlling source for Orange Book listings and patent information.[5]

For a mature hydrocortisone valerate product, the principal patent risk is more likely to arise from a later formulation, delivery device, or use patent than from the active ingredient itself.

Paragraph IV challenges

A Paragraph IV certification may be used where an ANDA applicant asserts that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed. Filing of a Paragraph IV notice can trigger patent litigation and, in applicable circumstances, a 30-month stay of approval under the Hatch-Waxman framework.[6]

For conventional hydrocortisone valerate cream, ointment, or lotion, the commercial value of a Paragraph IV challenge depends on:

• Whether the listed patent blocks approval.
• Remaining patent term.
• Number of competing ANDA applicants.
• Likelihood of a first-filer advantage.
• Expected generic price erosion.
• Litigation costs relative to product revenue.
• Whether the reference product has meaningful current sales.

Formulation and method-of-use patents

Potential patentable subject matter could include:

• A defined emulsion microstructure.
• A specific hydrocortisone valerate particle-size distribution.
• A preservative-free package.
• A foam or spray delivery system.
• A narrow excipient ratio that improves release or tolerability.
• Treatment of a specified dermatologic condition or anatomical site.
• A controlled application schedule.
• A combination with barrier-supportive ingredients.

These claims face validity and obviousness risks because topical corticosteroid vehicles and excipient classes are well developed. A defensible patent estate requires comparative data showing an unexpected technical or clinical result, not merely substitution of one conventional excipient for another.

How strong is the patent estate for hydrocortisone valerate?

The active-ingredient patent estate is commercially weak because hydrocortisone valerate has been used for decades. The strongest patent opportunities are product-specific and dependent on demonstrable formulation performance.

Patent category	Expected commercial strength
Core hydrocortisone valerate composition	Low
Conventional cream composition	Low to moderate
Specific microstructure with performance data	Moderate
Preservative-free package and delivery system	Moderate
Foam, spray, or metered delivery device	Moderate to strong if technically differentiated
Narrow method-of-use claim	Variable
Manufacturing process	Moderate if difficult to reproduce
Barrier-supportive combination	Moderate, subject to obviousness risk

Manufacturing know-how may be more valuable than patent protection. Control of particle size, mixing energy, temperature history, emulsion inversion, deaeration, and filling conditions can create a practical barrier even when competitors can legally practice the same broad formulation concept.

Which companies compete in hydrocortisone valerate?

Competition is fragmented across branded products, authorized generics, and generic dermatology manufacturers. Relevant competitive groups include:

• Companies marketing hydrocortisone valerate cream, ointment, or lotion.
• Generic dermatology manufacturers such as Taro, Perrigo, Fougera, and other ANDA holders, depending on current market status.
• Manufacturers of substitute corticosteroids.
• Contract development and manufacturing organizations with topical semi-solid capabilities.
• Specialty dermatology companies developing premium vehicles.

The closest therapeutic competitors are not limited to hydrocortisone valerate. Desonide may compete where lower potency or pediatric tolerability is preferred. Hydrocortisone butyrate, triamcinolone acetonide, fluocinolone acetonide, and betamethasone valerate may compete where physicians seek different potency, dosage forms, or price points.

How does hydrocortisone valerate compare with competing topical corticosteroids?

Product	Typical competitive position	Formulation opportunity
Hydrocortisone valerate 0.2%	Medium-potency option with established use	Better tolerability, packaging, cream or lotion convenience
Desonide 0.05%	Lower-potency option, often relevant to sensitive sites and pediatric use	Preservative-free and low-irritancy delivery
Hydrocortisone butyrate 0.1%	Similar therapeutic segment with established generic competition	Vehicle differentiation and application convenience
Triamcinolone acetonide 0.1%	Broadly used medium-potency corticosteroid	Lower-cost generic supply and multiple dosage forms
Fluocinolone acetonide	Low-to-medium potency depending on formulation	Oil, solution, scalp, and sensitive-skin positioning
Betamethasone valerate	Higher-potency competitive option in selected formulations	High-performance vehicles and limited-duration treatment

Hydrocortisone valerate’s opportunity is strongest where prescribers want more activity than low-potency hydrocortisone but do not want the profile of a higher-potency corticosteroid.

What commercial opportunities exist for hydrocortisone valerate?

Low-cost generic platform

A standard 0.2% cream, ointment, or lotion can be developed as a portfolio product using a common topical manufacturing platform. The commercial advantages are:

• Familiar active ingredient.
• Established clinical use.
• Straightforward pharmacy substitution when therapeutically equivalent.
• Limited need for physician education.
• Potential use of existing semisolid equipment.

The disadvantages are low differentiation and price pressure. This strategy requires low cost of goods, reliable supply, and efficient regulatory execution.

Premium tolerability platform

A fragrance-free, low-irritancy, cosmetically acceptable cream could target dermatology practices, pediatric care, and patients with recurrent eczema. Commercial claims should focus on attributes supported by testing, such as spreadability, reduced tack, or preservative avoidance.

Site-specific dosage forms

A lotion, solution, foam, or spray could target scalp, hairy skin, large body areas, or difficult-to-apply regions. Site-specific convenience creates a clearer commercial rationale than a small change to a conventional cream.

Combination and adjunctive products

A hydrocortisone valerate formulation with barrier-supportive excipients could be positioned for patients requiring both anti-inflammatory treatment and moisturization. Combination products raise regulatory and patent complexity but may support higher pricing if the vehicle improves adherence or reduces use of separate emollients.

Out-licensing and CDMO opportunities

Companies with topical formulation technology can license:

• A validated hydrocortisone valerate vehicle.
• A preservative-free package.
• A foam or metered delivery platform.
• A manufacturing process with improved content uniformity.
• A regional generic dossier.
• A dermatology portfolio including multiple corticosteroids.

The most attractive licensing asset is a platform that can be applied to several active ingredients, not a single mature corticosteroid product.

What manufacturing and intellectual-property barriers matter?

The main technical barriers are process control and performance reproducibility. Key controls include:

• API particle-size distribution.
• Drug crystal form.
• Uniformity during scale-up.
• Emulsion droplet size.
• Mixing and homogenization energy.
• Temperature during emulsification and cooling.
• Viscosity and rheology.
• Tube-filling shear.
• Preservative distribution.
• Long-term phase stability.

A formulation can pass chemical stability testing yet fail comparative release or structural characterization. Scale-up must therefore be designed around critical material attributes and critical process parameters rather than final assay alone. ICH quality-by-design principles support this approach.[7]

What generic launch scenarios exist?

Launch scenario	Timing and economics	Risk
First conventional ANDA after limited competition	Potentially favorable pricing and share capture	Patent certification and approval timing
Multiple simultaneous generic launches	Rapid price erosion	Low margin and pharmacy substitution pressure
Authorized generic or licensed generic	Faster commercial access through existing product	Lower differentiation
505(b)(2) foam or spray	Later launch with premium pricing potential	Higher clinical and regulatory cost
Preservative-free or device-enabled product	Niche premium opportunity	Package and microbiology complexity
Regional launch outside the U.S.	Potential lifecycle extension	Country-specific registration and reimbursement

Revenue exposure should be modeled using prescription volume, average selling price, pharmacy substitution, payer mix, dosage-form share, and competitor count. A mature topical corticosteroid can produce attractive gross margins only when manufacturing cost and launch competition are tightly controlled.

What is the FDA regulatory status of hydrocortisone valerate?

Hydrocortisone valerate is an FDA-recognized prescription topical corticosteroid active ingredient used in approved drug products. Product-specific approval status, therapeutic-equivalence ratings, discontinued status, labeling, and inactive ingredients must be assessed at the individual NDA or ANDA level through FDA databases and current labeling.[2,5]

FDA approval does not establish that every formulation containing hydrocortisone valerate is therapeutically interchangeable. Interchangeability depends on the approved product, dosage form, strength, route, and therapeutic-equivalence rating.

Key Takeaways

• Hydrocortisone valerate is a mature, genericized topical corticosteroid with limited active-ingredient exclusivity.
• The highest-value commercial opportunities involve cream tolerability, preservative minimization, improved packaging, scalp or hairy-area delivery, and premium vehicle design.
• A reference-aligned cream, ointment, or lotion is the lowest-risk ANDA strategy.
• Foam, spray, metered delivery, and materially different emulsion systems may justify a 505(b)(2) strategy.
• Q3 characterization, in vitro release, microstructure control, and scale-up reproducibility are central to topical development.
• Formulation patents require data showing a meaningful technical or clinical advantage.
• Manufacturing know-how may create a stronger practical barrier than broad excipient claims.
• Competition from desonide, hydrocortisone butyrate, triamcinolone acetonide, fluocinolone acetonide, and betamethasone valerate limits pricing power.
• Licensing value is highest for a reusable topical platform or differentiated delivery system.

FAQs

Can propylene glycol be removed from hydrocortisone valerate cream?

Yes, but removal can change drug solubility, release, preservative performance, viscosity, and skin penetration. A propylene-glycol-free product requires full comparative development and may no longer qualify as a simple formulation copy.

Is a hydrocortisone valerate foam likely to receive generic substitution?

Not automatically. A foam may have a different dosage form, vehicle, device, and bioequivalence burden. Therapeutic-equivalence status depends on the approved reference and FDA’s product-specific determination.

Are preservative-free hydrocortisone valerate products commercially attractive?

They can be attractive in sensitive-skin and pediatric segments, particularly with unit-dose or airless packaging. The premium must offset higher packaging, microbiology, and manufacturing costs.

Can ceramides be added without creating a new drug product?

Ceramides or other barrier-supportive ingredients can be incorporated, but their effect on drug release, penetration, labeling, and regulatory pathway must be addressed. A therapeutic claim involving hydrocortisone valerate remains subject to drug regulation.

Does hydrocortisone valerate have biosimilar competition?

No. Hydrocortisone valerate is a small-molecule corticosteroid, so competition occurs through generic drug pathways rather than the FDA biosimilar pathway.

References

1. U.S. Food and Drug Administration. (n.d.). Hydrocortisone valerate topical product labeling. DailyMed.
2. National Library of Medicine. (n.d.). DailyMed: Hydrocortisone valerate cream, ointment, and lotion labeling.
3. U.S. Food and Drug Administration. (2022). Physicochemical and structural (Q3) characterization of topical drug products submitted in ANDAs: Draft guidance for industry.
4. U.S. Food and Drug Administration. (2016). Topical dermatological corticosteroids: In vitro release testing and in vivo bioequivalence documentation: Draft guidance for industry.
5. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations.
6. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
7. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development.